[New options in patients with metastatic cancer of the colon already treated: platinum salts].
Cartei
G
G
Divisione di Oncologia Medica B, Centro di Riferimento Oncologico, Aviano. gcartei@ets.it
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D019454:Chronotherapy; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004260:DNA Repair; D004334:Drug Administration Schedule; D018432:Drug Resistance, Multiple; D004357:Drug Synergism; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D000077146:Irinotecan; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D000077150:Oxaliplatin; D016019:Survival Analysis
D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000077146:Irinotecan; D003520:Cyclophosphamide; D002945:Cisplatin; D005472:Fluorouracil; D002166:Camptothecin